By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug.

In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...

BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it ...